Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Turney Patricia A.						2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]									ck all applic Directo Officer	cable) or (give title	g Person(s) to Iss 10% Ov Other (s		ner
(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC. 2945 TOWNSGATE ROAD, SUITE 110						3. Date of Earliest Transaction (Month/Day/Year) 02/27/2020									below)	nior VP, M	Manu	below) facturing	
(Street) WESTLA	C	A	91361			4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
		Tab	le I - Noi	า-Deriv	ativ	e Se	curities	s Acc	quired, I	Disp	osed o	of, or B	ene	ficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amou Securitie Beneficia Owned F Reported	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	٧	Amount	(A) (D)	or	Price	Transact (Instr. 3	tion(s)			(5 4)
Common Stock 02/27/						2020		A		9,000 ⁽¹⁾ A		\$ <mark>0</mark>	9,0	9,000(2)		D			
		-	Table II -						ired, Di option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, 1	Code (In				6. Date Exe Expiration (Month/Day	Date	of Securities		curity	8. Price of Derivative Security (Instr. 5)		e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisabl		expiration pate	Title	OI N Of	umber					
Stock Option (Right to	\$27.61	02/27/2020			A		27,000		(3)	0	3/27/2030	Commo	n 2	7,000	\$0	27,00	0	D	

Explanation of Responses:

- 1. Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- 2. Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.
- 3. The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February

/s/ John W. Smither, as Attorney-in-Fact for Patricia A. 03/03/2020 Turnev

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.